

# Epidemiology of Recurrent Bacterial Bloodstream Infections in the US Military Health System



Alexander C. Vostal, MD<sup>1,2</sup>, Melissa Grance, BSc<sup>1,3</sup>, John H. Powers, III, MD<sup>4</sup>, M. Leigh Carson, MS<sup>1,3</sup>, Uzo Chukwuma, MPH<sup>5</sup>, Carlos Morales, MPH<sup>1,3</sup>, Charlotte Lanteri, PhD<sup>1</sup>, Nicholas Seliga, MPH<sup>5</sup>, Beth T. Poitras, MPH<sup>5</sup>, Edward Parmelee, MS<sup>1,3</sup>, Katrin Mende, PhD<sup>1,3,6</sup>

<sup>1</sup>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD;

<sup>2</sup>Division of Infectious Diseases, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD; <sup>3</sup>The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD;

<sup>4</sup>Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD; <sup>5</sup>Navy and Marine Corps Public Health Center, Portsmouth, VA; <sup>6</sup>Brooke Army Medical Center, JBSA Fort Sam Houston, TX

## Abstract

**Background:** The epidemiology of recurrent bacterial bloodstream infections (rBSI) has not been fully characterized. Evaluating rBSI represents opportunities to inform morbidity risk factors and prevention strategies. We describe the clinical and microbiological features of rBSI in the US Military Health System (MHS) in a prospective cohort study, including retired and active-duty US uniformed service members and their beneficiaries.

**Methods:** We collected data for rBSI episodes from MHS beneficiaries (Jan 2010 – Dec 2019). A rBSI is defined as growth of the same bacterial pathogen in blood culture >14 days after the index or previous episode. Demographics and comorbidities were collected prior to the index BSI. Microbiological data were obtained from the Navy and Marine Corps Public Health Center. Descriptive statistics are presented.

**Results:** A total of 12,749 beneficiaries were diagnosed with a BSI attributed to 1 of the 15 most common bacterial pathogens associated with BSI in the MHS, with 646 (5.1%) experiencing a rBSI. *Escherichia coli* had the largest proportion among all patients with rBSI (31% of 646); however, *Enterococcus* spp. accounted for the highest proportion of rBSI within a given pathogen subgroup (7.4% of 1,154 *Enterococcus* BSI; Table). *Pseudomonas aeruginosa* BSI had the shortest average time to recurrence (119 days), and *Acinetobacter* spp. had the highest frequency of BSI recurrences per patient (mean of 3). Male sex (59.9%) and age ≥65 years (52.9%) were most common among the rBSI patients. The updated Charlson Comorbidity index score preceding the index BSI was a median of 5.0, and chronic pulmonary disease (57.3%) and diabetes (56.6%) contributed the largest proportion of common comorbidities. A total of 88 (13%) rBSI patients had their index BSI while hospitalized following trauma where *S. aureus* was the most common (37.5%) bacterial pathogen.

**Conclusion:** Overall, the proportion of rBSI (5.1%) in our cohort of MHS beneficiaries was generally lower than that previously reported in the literature. Individuals with rBSI had a substantial burden of comorbid disease with 13% having trauma precede the index BSI. Identifying risk factors for recurrence may improve management strategies of primary BSI and may reduce morbidity of subsequent BSI.

## Background

- Recurrent bacterial BSI has been associated with increased mortality, especially in military trauma casualties
- Staphylococcus aureus* and *Escherichia coli* have been established as the most common primary bacterial BSI organisms, but less is known about the epidemiology of recurrent BSI
- The Military Health System (MHS) provides an opportunity for retrospective review of a cohort of patients with recurrent bacterial BSI
- These data will be used to describe epidemiologic and clinical features of recurrent bacterial BSI

## Methods

- Study population:** ≥18 years, MHS beneficiary with index BSI diagnosis treated at a MHS facility (Jan 2010 – Dec 2019) and attributed to a bacterial pathogen, and had a recurrent BSI
- Recurrent BSI was defined as growth of the same species of bacteria from blood culture >14 days after index or previous BSI episode
- Top 15 common and clinically-relevant bacterial pathogens were included in analysis (Table 1). Bacterial pathogens were subcategorized based on clinical similarities using 4 organism categories:
  - Lactose-fermenting Gram-negative bacilli, non-lactose-fermenting Gram-negative bacilli, *Staphylococcus aureus* and *Streptococcus* spp., and *Enterococcus* spp.
- Demographics were collected prior to index BSI
- Microbiologic data were obtained from Navy and Marine Corps Public Health Center

## Results

12,749 MHS beneficiaries with index bacterial BSI

- 646 (5.1%) beneficiaries with a recurrent BSI for a total of 679 recurrent BSI episodes

**Table 1: BSI recurrence, time to BSI recurrence (recurrence of the index pathogen), and mean number of episodes per pathogen**

Bacterial Species	Total Patients with BSI Episodes	Patients with Recurrent BSI Episodes, No. (%)	Average Days to Recurrence (SD)	Mean BSI Number (SD)
<i>Escherichia coli</i> <sup>#</sup>	4356	200 (4.6)	546.9 (603.9)	2.2 (0.4)
<i>Staphylococcus aureus</i>	2825	175 (6.2)	356.7 (475.2)	2.2 (0.6)
<i>Klebsiella pneumoniae</i> <sup>#</sup>	1272	81 (6.4)	327.1 (395.5)	2.2 (0.5)
<i>Enterococcus</i> spp.	1154	85 (7.4)	264.6 (448.7)	2.2 (0.5)
<i>Streptococcus</i> β-Hemolytic group	1018	56 (5.5)	554.9 (701.1)	2.2 (0.5)
<i>Streptococcus</i> spp.	1015	20 (2.0)	512.6 (686.4)	2.0 (0.0)
<i>Streptococcus viridans</i> group	989	15 (1.5)	508.7 (679.1)	2.1 (0.4)
<i>Streptococcus pneumoniae</i>	672	14 (2.1)	726.1 (710.7)	2.1 (0.4)
<i>Pseudomonas aeruginosa</i> <sup>§</sup>	556	20 (3.6)	118.8 (128.0)	2.2 (0.5)
<i>Serratia</i> spp. <sup>#</sup>	192	2 (1.0)	234.5 (289.2)	2.0 (0.0)
<i>Acinetobacter</i> spp. <sup>§</sup>	180	3 (1.7)	273.4 (411.2)	3.0 (1.7)
<i>Citrobacter</i> spp. <sup>#</sup>	141	3 (2.1)	259.7 (216.2)	2.0 (0.0)
<i>Enterobacter</i> spp. <sup>#</sup>	87	3 (3.4)	244.7 (119.5)	2.0 (0.0)
<i>Stenotrophomonas</i> spp. <sup>§</sup>	75	2 (2.7)	178.3 (206.8)	2.5 (0.7)
<i>Proteus</i> spp. <sup>#</sup>	19	0	0	0
<b>Total</b>	<b>12,749*</b>	<b>646*</b>		


<sup>#</sup> Lactose-fermenting Gram-negative bacilli. *Serratia* spp. included in this group based on clinical characteristics.

<sup>§</sup> non-Lactose-fermenting Gram-negative bacilli

\* not mutually exclusive

## Results (cont.)

**Figure 1: Distribution of bacterial pathogens for the 679 recurrent BSI episodes**



**Table 2: Age and sex for subcategorized recurrent BSI episodes**

Characteristics	Total Recurrent BSI Episodes, No. (%) (N=679)	BSI Episodes, No. (%)			
		Lactose-Fermenting GNB (N=289)	<i>Streptococcus</i> / <i>Enterococcus</i> spp. (N=190)	<i>Staphylococcus aureus</i> (N=175)	Non-Lactose-Fermenting GNB (N=25)
<b>Age Group, years</b>					
18-25	30 (4.4)	7 (2.4)	8 (4.2)	8 (4.6)	7 (28.0)
26-35	22 (3.2)	8 (2.8)	7 (3.7)	7 (4.0)	0
36-45	34 (5.0)	10 (3.5)	12 (6.3)	10 (5.7)	2 (8.0)
46-64	234 (34.5)	88 (30.5)	73 (38.4)	66 (37.7)	7 (28.0)
≥65	359 (52.9)	176 (60.9)	90 (47.4)	84 (48.0)	9 (36.0)
<b>Sex</b>					
Female	272 (40.1)	131 (45.3)	66 (34.7)	71 (40.6)	4 (16.0)
Male	407 (59.9)	158 (54.7)	124 (65.3)	104 (59.4)	21 (84.0)

GNB – Gram-negative bacilli

**Table 3: Ten most frequent comorbidities associated with recurrent BSI episodes**

Comorbidity, No. (%)	Total Recurrent BSI Episodes (N=679)*
Chronic pulmonary disease	389 (57.3)
Diabetes without chronic complication	384 (56.6)
Renal disease	301 (44.3)
Any malignancy (except malignant neoplasms of the skin)	296 (43.6)
Peripheral vascular disease	262 (38.6)
Congestive heart failure	259 (38.1)
Cerebrovascular disease	244 (35.9)
Diabetes with chronic complication	235 (34.6)
Mild liver disease	195 (28.7)
Myocardial infarction	144 (21.2)

\* not mutually exclusive

## Results (cont.)

**Table 4: Frequency of recurrent BSI episodes with a preceding trauma event**

Characteristics, No. (%)	Total Recurrent BSI Episodes (N=679)	Recurrent BSI Episodes with Preceding Trauma Event (N=88)
Lactose-Fermenting GNB	289 (42.6)	27 (30.7)
<i>Streptococcus</i> / <i>Enterococcus</i> spp.	190 (28.0)	20 (22.7)
<i>Staphylococcus aureus</i>	175 (25.8)	33 (37.5)
Non-Lactose-Fermenting GNB	25 (3.7)	8 (9.1)

GNB – Gram-negative bacilli

- Trauma was associated with 13% of recurrent BSI episodes with open extremity wounds being the most frequent trauma diagnosis (24%, 21 of 88)
- Burns occurred in 7 (8%) of 88 recurrent BSI with a preceding trauma diagnosis

## Conclusions

- The burden of recurrent BSI among MHS beneficiaries is 5.1% of all BSI episodes reported during a ten-year period
- Trauma preceded 13% of recurrent BSI episodes, indicating the burden of this disease process in a military population
- Further evaluation of risk factors surrounding index BSI may elicit management strategies to prevent mortality in subsequent BSI episodes

## Acknowledgments

This project has been funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072, a NIAID grant (award #:HU00011820031) and the Defense Health Program, U.S. DoD, under award HU0001190002. Funded by the NCI Contract No.75N910D00024, Task Order No.75N91019F00130.

**Disclaimer.** The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., National Institutes of Health or the Department of Health and Human Services, Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Departments of the Air Force, Navy, Army, or the Department of Defense or the U.S. Government. This research has been approved by USU IRB. Some of the authors are employees of the U.S. Government. This work was prepared as part of official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military Service member or employee of the U.S. Government as part of that person's official duties.



## Correspondence

Dr. Alexander Vostal; [avostal@som.umaryland.edu](mailto:avostal@som.umaryland.edu)